Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

BACKGROUND & AIMS: Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Clin Gastroenterol Hepatol
Główni autorzy: Lynch, Kate D., Chapman, Roger W., Keshav, Satish, Montano-Loza, Aldo J., Mason, Andrew L., Kremer, Andreas E., Vetter, Marcel, de Krijger, Manon, Ponsioen, Cyriel Y., Trivedi, Palak, Hirschfield, Gideon, Schramm, Christoph, Liu, Chung Heng, Bowlus, Christopher L., Estes, Derek J., Pratt, Daniel, Hedin, Charlotte, Bergquist, Annika, de Vries, Annemarie C., van der Woude, C. Janneke, Yu, Lei, Assis, David N., Boyer, James, Ytting, Henriette, Hallibasic, Emina, Trauner, Michael, Marschall, Hanns-Ulrich, Daretti, Luigi M., Marzioni, Marco, Yimam, Kidist K., Perin, Nicola, Floreani, Annarosa, Beretta-Piccoli, Benedetta Terziroli, Rogers, Jennifer K., Levy, Cynthia
Format: Artigo
Język:Inglês
Wydane: W.B. Saunders for the American Gastroenterological Association 2020
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941216/
https://ncbi.nlm.nih.gov/pubmed/31100458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2019.05.013
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy